Cargando…

Construction and validation of a novel nomogram to predict cancer-specific survival in patients with gastric adenocarcinoma

BACKGROUND AND AIMS: Adenocarcinoma is one of the most common pathological types of gastric cancer. The aims of this study were to develop and validate prognostic nomograms that could predict the probability of cancer-specific survival (CSS) for gastric adenocarcinoma (GAC) patients at 1, 3, and 5 y...

Descripción completa

Detalles Bibliográficos
Autores principales: Nie, Guole, Zhang, Honglong, Yan, Jun, Xie, Danna, Zhang, Haijun, Li, Xun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948249/
https://www.ncbi.nlm.nih.gov/pubmed/36845677
http://dx.doi.org/10.3389/fonc.2023.1114847
_version_ 1784892739866853376
author Nie, Guole
Zhang, Honglong
Yan, Jun
Xie, Danna
Zhang, Haijun
Li, Xun
author_facet Nie, Guole
Zhang, Honglong
Yan, Jun
Xie, Danna
Zhang, Haijun
Li, Xun
author_sort Nie, Guole
collection PubMed
description BACKGROUND AND AIMS: Adenocarcinoma is one of the most common pathological types of gastric cancer. The aims of this study were to develop and validate prognostic nomograms that could predict the probability of cancer-specific survival (CSS) for gastric adenocarcinoma (GAC) patients at 1, 3, and 5 years. METHODS: In total, 7747 patients with GAC diagnosed between 2010 and 2015, and 4591 patients diagnosed between 2004 and 2009 from the Surveillance, Epidemiology, and End Results (SEER) database were included in this study. The 7747 patients were used as a prognostic cohort to explore GAC-related prognostic risk factors. Moreover, the 4591 patients were used for external validation. The prognostic cohort was also divided into a training and internal validation sets for construction and internal validation of the nomogram. CSS predictors were screened using least absolute shrinkage and selection operator regression analysis. A prognostic model was built using Cox hazard regression analysis and provided as static and dynamic network-based nomograms. RESULTS: The primary site, tumor grade, surgery of the primary site, T stage, N stage, and M stage were determined to be independent prognostic factors for CSS and were subsequently included in construction of the nomogram. CSS was accurately estimated using the nomogram at 1, 3, and 5 years. The areas under the curve (AUCs) for the training group at 1, 3, and 5 years were 0.816, 0.853, and 0.863, respectively. Following internal validation, these values were 0.817, 0.851, and 0.861. Further, the AUC of the nomogram was much greater than that of American Joint Committee on Cancer (AJCC) or SEER staging. Moreover, the anticipated and actual CSS values were in good agreement based on decision curves and time-calibrated plots. Then, patients from the two subgroups were divided into high- and low-risk groups based on this nomogram. The survival rate of high-risk patients was considerably lower than that of low-risk patients, according to Kaplan–Meier (K-M) curves (p<0.0001). CONCLUSIONS: A reliable and convenient nomogram in the form of a static nomogram or an online calculator was constructed and validated to assist physicians in quantifying the probability of CSS in GAC patients.
format Online
Article
Text
id pubmed-9948249
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99482492023-02-24 Construction and validation of a novel nomogram to predict cancer-specific survival in patients with gastric adenocarcinoma Nie, Guole Zhang, Honglong Yan, Jun Xie, Danna Zhang, Haijun Li, Xun Front Oncol Oncology BACKGROUND AND AIMS: Adenocarcinoma is one of the most common pathological types of gastric cancer. The aims of this study were to develop and validate prognostic nomograms that could predict the probability of cancer-specific survival (CSS) for gastric adenocarcinoma (GAC) patients at 1, 3, and 5 years. METHODS: In total, 7747 patients with GAC diagnosed between 2010 and 2015, and 4591 patients diagnosed between 2004 and 2009 from the Surveillance, Epidemiology, and End Results (SEER) database were included in this study. The 7747 patients were used as a prognostic cohort to explore GAC-related prognostic risk factors. Moreover, the 4591 patients were used for external validation. The prognostic cohort was also divided into a training and internal validation sets for construction and internal validation of the nomogram. CSS predictors were screened using least absolute shrinkage and selection operator regression analysis. A prognostic model was built using Cox hazard regression analysis and provided as static and dynamic network-based nomograms. RESULTS: The primary site, tumor grade, surgery of the primary site, T stage, N stage, and M stage were determined to be independent prognostic factors for CSS and were subsequently included in construction of the nomogram. CSS was accurately estimated using the nomogram at 1, 3, and 5 years. The areas under the curve (AUCs) for the training group at 1, 3, and 5 years were 0.816, 0.853, and 0.863, respectively. Following internal validation, these values were 0.817, 0.851, and 0.861. Further, the AUC of the nomogram was much greater than that of American Joint Committee on Cancer (AJCC) or SEER staging. Moreover, the anticipated and actual CSS values were in good agreement based on decision curves and time-calibrated plots. Then, patients from the two subgroups were divided into high- and low-risk groups based on this nomogram. The survival rate of high-risk patients was considerably lower than that of low-risk patients, according to Kaplan–Meier (K-M) curves (p<0.0001). CONCLUSIONS: A reliable and convenient nomogram in the form of a static nomogram or an online calculator was constructed and validated to assist physicians in quantifying the probability of CSS in GAC patients. Frontiers Media S.A. 2023-02-09 /pmc/articles/PMC9948249/ /pubmed/36845677 http://dx.doi.org/10.3389/fonc.2023.1114847 Text en Copyright © 2023 Nie, Zhang, Yan, Xie, Zhang and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Nie, Guole
Zhang, Honglong
Yan, Jun
Xie, Danna
Zhang, Haijun
Li, Xun
Construction and validation of a novel nomogram to predict cancer-specific survival in patients with gastric adenocarcinoma
title Construction and validation of a novel nomogram to predict cancer-specific survival in patients with gastric adenocarcinoma
title_full Construction and validation of a novel nomogram to predict cancer-specific survival in patients with gastric adenocarcinoma
title_fullStr Construction and validation of a novel nomogram to predict cancer-specific survival in patients with gastric adenocarcinoma
title_full_unstemmed Construction and validation of a novel nomogram to predict cancer-specific survival in patients with gastric adenocarcinoma
title_short Construction and validation of a novel nomogram to predict cancer-specific survival in patients with gastric adenocarcinoma
title_sort construction and validation of a novel nomogram to predict cancer-specific survival in patients with gastric adenocarcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948249/
https://www.ncbi.nlm.nih.gov/pubmed/36845677
http://dx.doi.org/10.3389/fonc.2023.1114847
work_keys_str_mv AT nieguole constructionandvalidationofanovelnomogramtopredictcancerspecificsurvivalinpatientswithgastricadenocarcinoma
AT zhanghonglong constructionandvalidationofanovelnomogramtopredictcancerspecificsurvivalinpatientswithgastricadenocarcinoma
AT yanjun constructionandvalidationofanovelnomogramtopredictcancerspecificsurvivalinpatientswithgastricadenocarcinoma
AT xiedanna constructionandvalidationofanovelnomogramtopredictcancerspecificsurvivalinpatientswithgastricadenocarcinoma
AT zhanghaijun constructionandvalidationofanovelnomogramtopredictcancerspecificsurvivalinpatientswithgastricadenocarcinoma
AT lixun constructionandvalidationofanovelnomogramtopredictcancerspecificsurvivalinpatientswithgastricadenocarcinoma